CEC has multiple ANCC-accredited presentations for your ONS chapter meetings.

If you're interested in hosting an IN-PERSON or VIRTUAL chapter meeting, please click on your preferred option below. Each activity offers 1 hour of ANCC credit. CEC will provide the speaker, accreditation, educational materials, etc.

Dates are filling fast - register your chapter today!

CLICK ON THE IMAGE OR EMAIL JESSICA HALL AT hallj@ceconcepts.com TO INQUIRE

Program Overview: 

Strategically designed to foster an understanding of both the disease state complexity and far-reaching racial disparity intrinsic to triple-negative breast cancer (TNBC), this educational session will begin with an appraisal of TNBC pathophysiology and the multifaceted etiologies of the disparate outcomes seen among African-American patients. Expert faculty will then guide attendees through a real-world exploration of antibody-drug conjugates, including structure, mechanism of action, and a dedicated focus on the effective anticipation, recognition, and mitigation of adverse events. Finally, attendees will take part in an interactive case-based discussion centered on how the oncology nurse can provision patient-centric care that is both efficacious and equitable through the incorporation of novel therapeutic approaches and the adoption of renewed perspectives.

Learning Objectives:

• Discuss the multifaceted etiology of the racial disparity observed in triple-negative breast cancer (TNBC), with a focus on both biologic and non-biologic factors, and identify tangible strategies oncology nurses can employ to promote equitable care and outcomes for all patients.
• Review antibody-drug conjugate (ADC) structure, mechanism of action, and real-world clinical considerations, with a particular focus on toxicity management, for oncology nurses who care for TNBC patients receiving ADCs.
• Examine completed, ongoing, and planned clinical trial data for ADCs as part of the expanding TNBC treatment calculus, including recent FDA approvals and updated guideline recommendations.
• Using a patient case-driven approach, design evidence-based treatment plans for patients with TNBC, with an emphasis on the placement of novel therapies in the shifting TNBC treatment calculus, strategies for anticipating, recognizing, and treating adverse events, and effectively integrating socioeconomic and other non-biologic factors into equitable cancer care.

Program Overview:

Join our expert Nursing faculty as they review immune checkpoint inhibitor (ICI) data across bladder cancer treatment, from NMIBC to MIBC to locally advanced/metastatic disease. Our experts also will provide an understanding of effective therapeutic sequencing of platinum-based chemotherapy, ICIs, targeted therapies, and antibody-drug conjugates, as well as integration of novel combinatorial regimens in both first-line and later lines of therapy. Finally, our expert faculty will conclude with nursing-centric insights for anticipating and managing immune-mediated adverse events (imAEs) in patients receiving ICIs to deliver effective nursing care to their patients with bladder cancer.

Learning Objectives:

• Appraise the expanding clinical trial evidentiary base across all stages of the bladder cancer disease continuum, including newly-approved indications, recently-reported data, and current consensus guideline recommendations for treatment of NMIBC, MIBC, and locally advanced/mUC.
• Examine the evolving bladder cancer management calculus, with a focus on evidence-based treatment sequencing strategies and/or combinatorial regimens incorporating platinum chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates.  
• Review practical patient counseling strategies related to the safety, efficacy, and therapeutic rationale of novel treatments in bladder cancer, with an emphasis on the provision of adaptive emotional support infrastructures.
• Identify immune-mediated adverse events (imAEs) that may occur in patients with bladder cancer receiving immune checkpoint inhibitors, either as monotherapy or in combination, and implement adaptive imAE anticipation, recognition, and management strategies.

Program Overview:

Strategically designed to foster an understanding of both the disease state complexity and far-reaching disparity intrinsic to endometrial cancer, this educational session will begin with an appraisal of the utility and importance of biomarker testing in advanced endometrial cancer, and the latest data related to immune checkpoint inhibitor treatments in advanced endometrial cancer. The role of the oncology nurse in mitigating and managing toxicities with these agents will also be explored. Finally, expert faculty will then guide attendees through a real-world interactive case-based discussion centered on how the oncology nurse can provision patient-centric care that is both efficacious and equitable through the incorporation of novel immune checkpoint inhibitor therapies and the adoption of renewed perspectives.

Learning Objectives:

• Identify the predictive biomarkers that allow for tailored treatment options for patients with endometrial cancer, exploring the role of the oncology nurse in molecular testing.
• Appraise recent clinical evidence on the safety and efficacy of immune checkpoint inhibitor monotherapy and combinatorial regimens for the treatment of advanced or recurrent endometrial cancer.
• Analyze the unique toxicities of immune checkpoint inhibitors for endometrial cancer and important considerations for both monitoring and managing adverse events.
• Use a case-based approach to recognize and address socioeconomic and racial disparities affecting health outcomes in endometrial cancer patients and how the oncology nurse can provide patient-centric care that is both efficacious and equitable.